The Current Status of Antisense Gene Therapies for Bacteria-caused Diseases Challenges and Opportunities

被引:1
|
作者
Li, Jiawei [1 ]
Liang, Xuejun [1 ]
Wang, Fangxin [2 ]
Wang, Juping [1 ]
Ding, Feng [1 ,2 ]
机构
[1] Youjiang Med Univ Nationalities, Sch Basic Med Sci, Dept Etiol Biol, Baise 533000, Guangxi, Peoples R China
[2] Wenzhou Med Univ, Sch Basic Med Sci, Dept Microbiol & Immunol, Wenzhou 325035, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
Bacterial diseases; drug resistance; gene therapy; antisense oligonucleotides; CRISPR-Cas9; mRNA; RESISTANT STAPHYLOCOCCUS-AUREUS; IN-VIVO DELIVERY; ESCHERICHIA-COLI; ACCESSIBLE SITES; WEB SERVER; OLIGONUCLEOTIDE THERAPIES; GENOMIC DNA; RNA; PEPTIDE; INHIBITION;
D O I
10.2174/1381612829666230118152428
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Bacteria-caused diseases continue to pose a serious threat to human health. The current situation of overused antibiotics against those diseases further spurs and exacerbates the ever-increasing drug resistance problems, which really leaves us very few options to combat those nasty bugs. Gene therapies based on the antisense oligonucleotide, though developed more than 40 years ago, did not reform the current treatments as originally expected. Along with the advances of new delivery technologies, this old field thrives again. In addition, newly evolving gene-editing tools based on the CRISPR-Cas system shed new light on this old field, bringing a breeze of hope to gene therapies for bacteria-caused diseases. As a fast-growing field, we strive to summarize in this review the recent progress in using gene therapies in those areas, analyze the potential challenges or problems from using antisense or gene-editing tools for targeting bacterial diseases and seek to explore any potential solutions to the current dilemmas. As a short review, we will focus our discussion mainly on antisense oligonucleotide-based gene therapies while briefly touching on the CRISPR-Cas based ones as the latter is just beginning to get more attention for application in the prokaryotic kingdom.
引用
收藏
页码:272 / 282
页数:11
相关论文
共 50 条
  • [1] Opportunities and challenges for antisense oligonucleotide therapies
    Kuijper, Elsa C.
    Bergsma, Atze J.
    Pijnappel, W. W. M. Pim
    Aartsma-Rus, Annemieke
    JOURNAL OF INHERITED METABOLIC DISEASE, 2021, 44 (01) : 72 - 87
  • [2] Molecular Therapies for Inherited Retinal Diseases-Current Standing, Opportunities and Challenges
    Vazquez-Dominguez, Irene
    Garanto, Alejandro
    Collin, Rob W. J.
    GENES, 2019, 10 (09)
  • [3] Gene-based therapies in lipidology: current status and future challenges
    Gaudet, Daniel
    Brisson, Diane
    CURRENT OPINION IN LIPIDOLOGY, 2015, 26 (06) : 553 - 565
  • [4] Bacteria-mediated cancer therapies: opportunities and challenges
    Yang, Meiyang
    Yang, Fuwei
    Chen, Weijun
    Liu, Shenhuan
    Qiu, Lipeng
    Chen, Jinghua
    BIOMATERIALS SCIENCE, 2021, 9 (17) : 5732 - 5744
  • [5] Phosphorene: Current status, challenges and opportunities
    Goswami, Anandarup
    Gawande, Manoj B.
    FRONTIERS OF CHEMICAL SCIENCE AND ENGINEERING, 2019, 13 (02) : 296 - 309
  • [6] Phosphorene: Current status, challenges and opportunities
    Anandarup Goswami
    Manoj B. Gawande
    Frontiers of Chemical Science and Engineering, 2019, 13 : 296 - 309
  • [7] Remimazolam – current status, opportunities and challenges
    J. Robert Sneyd
    Anesthesiology and Perioperative Science, 1 (3):
  • [8] Borophene: Current Status, Challenges and Opportunities
    Hou, Chuang
    Tai, Guoan
    Wu, Zenghui
    Hao, Jinqian
    CHEMPLUSCHEM, 2020, 85 (09): : 2186 - 2196
  • [9] Anaerobic biorefinery: Current status, challenges, and opportunities
    Sawatdeenarunat, Chayanon
    Nguyen, Duc
    Surendra, C.
    Shrestha, Shilva
    Rajendran, Karthik
    Oechsner, Hans
    Xie, Li
    Khanal, Samir Kumar
    BIORESOURCE TECHNOLOGY, 2016, 215 : 304 - 313
  • [10] Pharmacogenomics in Lebanon: current status, challenges and opportunities
    Chidiac, Lorenzo
    Yazbeck, Hady
    Mahfouz, Rami
    Zgheib, Nathalie K.
    PHARMACOGENOMICS JOURNAL, 2024, 24 (03):